Brokerages Set Veru Inc (VERU) Price Target at $5.13

Shares of Veru Inc (NASDAQ:VERU) have been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $5.25.

Several equities analysts recently issued reports on the stock. ValuEngine lowered shares of Veru from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Zacks Investment Research lowered shares of Veru from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. HC Wainwright set a $5.00 price objective on shares of Veru and gave the company a “buy” rating in a report on Wednesday. Oppenheimer assumed coverage on shares of Veru in a report on Tuesday, March 19th. They set an “outperform” rating and a $5.00 price objective on the stock. Finally, Maxim Group set a $6.00 price objective on shares of Veru and gave the company a “buy” rating in a report on Thursday, February 14th.

Shares of VERU stock opened at $2.00 on Monday. The company has a market cap of $123.70 million, a P/E ratio of -5.13 and a beta of 0.41. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.99 and a current ratio of 1.25. Veru has a 52-week low of $1.18 and a 52-week high of $2.37.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.01). The business had revenue of $6.98 million for the quarter, compared to analysts’ expectations of $6.98 million. Veru had a negative net margin of 91.61% and a negative return on equity of 64.91%. Sell-side analysts anticipate that Veru will post -0.17 earnings per share for the current fiscal year.

In other news, insider Mitchell Shuster Steiner sold 20,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $1.43, for a total transaction of $28,600.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 99,899 shares of company stock worth $148,683 over the last ninety days. Corporate insiders own 29.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp lifted its position in Veru by 16.2% during the first quarter. Northern Trust Corp now owns 54,178 shares of the company’s stock valued at $79,000 after purchasing an additional 7,542 shares during the period. BlackRock Inc. lifted its position in Veru by 7.5% during the first quarter. BlackRock Inc. now owns 138,404 shares of the company’s stock valued at $202,000 after purchasing an additional 9,638 shares during the period. Vanguard Group Inc lifted its position in Veru by 1.2% during the third quarter. Vanguard Group Inc now owns 1,199,963 shares of the company’s stock valued at $1,704,000 after purchasing an additional 13,650 shares during the period. Renaissance Technologies LLC lifted its position in Veru by 48.7% during the first quarter. Renaissance Technologies LLC now owns 92,610 shares of the company’s stock valued at $135,000 after purchasing an additional 30,310 shares during the period. Finally, Charles Schwab Investment Management Inc. acquired a new position in Veru during the first quarter valued at $48,000. Institutional investors own 8.85% of the company’s stock.

Veru Company Profile

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Read More: Put Option Volume

Analyst Recommendations for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.